Alpha Cognition Inc.
Close on Oct 19, 2026
- Market cap
- $185.08M
- P/E (TTM)
- –
- Dividend yield
- –
About Alpha Cognition
Biological Products, (No Diagnostic Substances), SIC 2836
Alpha Cognition Inc. is a biopharmaceutical company that develops and commercializes therapies for neurodegenerative conditions, primarily Alzheimer’s disease. Its principal commercial offering is ZUNVEYL, an oral delayed-release tablet indicated for adults suffering from mild to moderate Alzheimer’s dementia. The company also pursues preclinical programs combining ZUNVEYL with memantine and developing sublingual formulations for cognitive impairment following mild traumatic brain injuries. Its target market comprises long-term care facilities, including nursing home physicians, healthcare teams, consultant pharmacists, and institutional pharmacies that care for elderly patients.
The company is headquartered in Grapevine, Texas, and is incorporated under the laws of British Columbia. Its commercial operations are based in the United States, where its medication is stocked and available through pharmacies nationwide. Alpha Cognition relies on contract manufacturing organizations in Taiwan for active pharmaceutical ingredients and facilities in the United States for tablet manufacturing. The company also holds an exclusive licensing agreement covering development and commercialization across Australia, New Zealand, and Asian territories excluding Japan.
Summary of the business section of Alpha Cognition's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Alpha Cognition Inc.
- Headquarters
- Grapevine, TX
- Address
- 1452 Hughes Rd., Ste. 200 76051
- Phone
- (858) 344-4375
- Employees
- 72, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- A1
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C., New York, New York
Stock & identifiers
- Ticker
- ACOG
- Exchange
- Nasdaq
- IPO date
- Nov 13, 2024
- Shares outstanding
- 22M, Aug 13, 2026
- Public float
- $149.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-25 reverse, Nov 14, 2024
- SEC CIK
- 1655923
- CUSIP
- 02074J501
- ISIN
- US02074J5011
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael E. McFadden | Chief Executive Officer, Director | 204,691 |
| Lauren D'Angelo | Chief Operating Officer | 140,695 |
| Henry Huy Du | VP Finance and Accounting | 20,579 |
| Robert James Wills | Director | 32,241 |
| Bethany Sensenig | Director | 5,489 |
| Leonard Powell Mertz | Director | 267,239 |
| Phillip Joseph Mertz | Director | 42,263 |
| Rajeev Kumar Bakshi | Director | 19,084 |
| Kenneth Anthony Cawkell | Director | 225,717 |
| John Prentiss Havens | Director | 285,587 |
Employees
Headcount reported in annual reports
“As of March 30, 2026, we had 72 full-time employees”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 15, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 14, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 13, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 8, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Oct 9, 2019 | Name change | Name changed from Neurodyn Cognition Inc. to Alpha Cognition Inc. |